

Thomas J. Pugh M.D.

Present Title and Affiliation

Director 3/2020-Present
The Urology Center of Colorado
Department of Radiation Oncology

Previous Appointments/Titles

Vice-Chair for Clinical Affairs 7/2018-2/2020
University of Colorado Hospital System
Department of Radiation Oncology

Director of Genitourinary Cancer Clinical Services 7/2018-2/2020
and Research
University of Colorado Hospital System
Department of Radiation Oncology

Associate Residency Program Director 10/2016-2/2020
Radiation Oncology
University of Colorado School of Medicine

Associate Professor 11/2015-2/2020
University of Colorado School of Medicine
Department of Radiation Oncology

Assistant Professor 7/2010-10/2015
University of Texas MD Anderson Cancer Center
Department of Radiation Oncology
Division of Radiation Oncology

Director of Educational Programs 12/2013-10/2015
Prostate Brachytherapy
University of Texas MD Anderson Cancer Center
Department of Radiation Oncology
Division of Radiation Oncology

Clinical Trials Lead – Genitourinary Section 06/2014-10/2015
University of Texas MD Anderson Cancer Center
Department of Radiation Oncology
Division of Radiation Oncology

Degree-Granting Education

University of Colorado Health Science Center Medical Doctorate Honors Graduate	Denver, CO 8/2001-5/2005
University of Kansas Bachelor of Arts Major: Psychology	Lawrence, KS 8/1995-5/1999

Post-Graduate Training

Clinical Fellow: Prostate Brachytherapy American Brachytherapy Society Seattle Prostate Institute	Seattle, WA 12/2009-1/2010
Chief Resident: Radiation Oncology University of Colorado Denver	Denver, CO 7/2009-6/2010
Clinical Residency: Radiation Oncology University of Colorado Denver	Denver, CO 6/2006-6/2009
Clinical Internship: Internal Medicine University of Colorado Denver	Denver, CO 6/2005-6/2006

Board Certification/Medical Licensure

National Board of Medical Examiners	10/2006
Texas State Medical License #N5953	Expired 11/2015
American Board of Radiology: Radiation Oncology, #60743	Expires 05/2021
Colorado State Medical License DR.0056012	Expires 04/2019

Awards/Honors

2018	Featured Expert in Applied Radiation Oncology. "Radiation therapy improved survival of prostate cancer patients with low burden of metastases".
------	---

- 2017 American Society of Radiation Oncology (ASTRO) Top 20 Poster Award (Genitourinary Cancer Tract)
- 2016 American College of Radiology Editor's Choice for Radiation Oncology November 2016: Improved Survival with Prostate Radiation in Addition to Androgen Deprivation Therapy for Men with Newly Diagnosed Metastatic Prostate Cancer.
- 2012 Featured Original Research Article "Proton therapy for prostate cancer" Medical Physics Web Webinar
- 2009 RTOG Travel Grant Award. Summer Semi-Annual Meeting.
- 2009 ASCO/AACR Methods in Clinical Cancer Research Fellowship. Awarded to 75 post-graduate trainees internationally.
- 2009 American Brachytherapy Society (ABS) Seattle Prostate Institute Fellowship Award.
- 2009 American Radium Society Young Oncologist Essay Award, Travel Grant, and Honorarium.
- 2008 ASTRO Annual Poster Recognition Award for Excellence in Clinical Research
- 2001 Recipient NIH T32 Institutional Summer Research Grant
- 1999 Elected Member Phi Beta Kappa
- 1999 GTE NCAA Academic All American: Men's Basketball District 7
- 1999 NCAA Post-Graduate Scholarship Recipient: Awarded to seven student-athletes nationally
- 1999 University of Kansas Varsity Men's Basketball Captain Award
- 1998 Big XII Conference Student Athlete of the Year: Men's Basketball
- 1995-1999 All Big VIII/Big XII Conference All Conference Academic First Team
- 1995-1999 4-Time University of Kansas Student Athlete of the Year

Professional Activities

- UCHealth Anschutz Medical Campus Radiation Oncology Quality and Safety Committee – Co-Chair; 1/2019- 2/2020
- UCHealth Anschutz Medical Campus Radiation Oncology Clinical Operations Committee – Co-Chair; 1/2019-2/2020
- UCHealth Anschutz Medical Campus Executive Council Member 06/2018-2/2020
- University of Colorado School of Medicine Clinical Leadership Committee – Voting Member 6/2018-2/2020
- Medical Practice Director – University of Colorado Hospital Radiation Oncology 6/2018-2/2020
- ABS-GEC-ESTRO Prostate Brachytherapy Collaborative Group – ABS 2/2018-2/2020
- American Brachytherapy Society (ABS)/MD Anderson Cancer Center LDR/HDR Prostate Brachytherapy School Faculty – 2018
- American Brachytherapy Society (ABS) Prostate School Faculty - 2017
- Southwest Oncology Group (SWOG) – Clinical Investigator and Genitourinary Steering Committee Member, 5/2017-2/2020
- Radiation Therapy Quality Reviewer – NRG Oncology Protocol GU003, 6/2017-7/2018
- National Comprehensive Cancer Network Prostate Cancer Guidelines Panel Member, 2/2017 – 2/2020
- ASCO Genitourinary Cancer Symposium Planning Committee Member, 3/2017-2/2020
- American Brachytherapy Society (ABS) Resident Outreach Committee – Chair; 7/2017- 2/2020
- American Board of Radiology (ABR) Examiner and Member or Genitourinary Cancer Committee, 12/2016 - 2/2020
- Prostate Cancer Results Study Group (PCRS) – Panel Member, 9/2016 –2/2020

- University of Colorado Dosimetry Constraints Working Group – Member 12/2015-1/2017
- NRG Oncology/Radiation Therapy Oncology Group (RTOG): Genitourinary Cancer Research Steering Committee 1/2012-2/2020
- American Brachytherapy Society: Membership Committee 1/2013-2/2020
- MD Anderson Physician’s Network Consultant, 7/2011-6/2015
- ASTRO Disciplines of Leadership Training Course; Miami, FL 10/2014
- Elekta Magnetic Resonance Imaging-Linear Accelerator Integration Project – Team Leader Genitourinary Cancers 9/2012-10/2015
- University of Texas MD Anderson Houston Clinical Research Committee – Member 9/2013-8/2014
- MD Anderson PTC Clinical Operations Efficiency Committee – Project Leader 4/2014-10/2015
- Member of American Society of Therapeutic Radiology and Oncology (ASTRO)
- Member of American Society of Clinical Oncology (ASCO)
- Member of American Brachytherapy Society (ABS)
- Member of American College of Radiology (ACR)
- Member of American Radium Society (ARS)
- Member of Particle Therapy Co-operative Group (PTCOG)

Peer Reviewed Original Manuscripts

1. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, **Pugh TJ**, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. *J Clin Oncol* 27(10):1572-8, 4/2009. e-Pub 3/2009.
2. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, **Pugh TJ**, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic

- body radiation therapy for lung metastases. *J Clin Oncol* 27(10):1579-84, 4/2009. e-Pub 3/2009.
3. **Pugh TJ**, Ballonoff A, Rusthoven KE, McCammon R, Kavanagh B, Newman F, Rabinovitch R. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis. *Int J Radiat Oncol Biol Phys* 76(3):845-9, 3/2010. e-Pub 6/2009.
 4. **Pugh TJ**, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. *Cancer* 116(16):3843-51, 8/2010.
 5. **Pugh TJ**, Gaspar LE. Stage III non-small cell lung cancer and brain metastases: the role of radiation therapy." *European Journal of Clinical and Medical Oncology* 2(5):1-5.
 6. **Pugh TJ**, Chen C, Rabinovitch R, Eckhardt SG, Rusthoven KE, Swing R, Raben D. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. *Int J Radiat Oncol Biol Phys* 78(2):521-6, 10/2010. e-Pub 2/2010.
 7. Samuelian JM, Swanson DA, Kudchadker RJ, **Pugh TJ**, Kuban DA, Lee AK, Choi S, Nguyen QN, Bruno TL, Frank SJ. Long-term Tumor Control After Brachytherapy for Cancer at the Base of the Prostate. *Journal of Contemporary Brachytherapy* 3(4):183-187. e-Pub 4/2011.
 8. **Pugh TJ**, Lee AK. Role of radiation therapy for the treatment of lymph nodes in urologic malignancies. *Urol Clin North Am* 38(4):497-506, 11/2011.
 9. Kim MM, Hoffman KE, Levy LB, Frank SJ, **Pugh TJ**, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in prostate cancer survival over time: a 20-year analysis. *Cancer J* 18(1):1-8, Jan-Feb, 1/2012.
 10. Frank SJ, Levy LB, van Vulpen M, Crook J, Sylvester J, Grimm P, **Pugh TJ**, Swanson DA. Outcomes after prostate brachytherapy are even better than predicted. *Cancer* 118(3):839-47, 2/2012. e-Pub 7/2011.
 11. Kudchadker RJ, **Pugh TJ**, Swanson DA, Bruno TL, Bolukbasi Y, Frank SJ. Preoperative treatment planning with intraoperative optimization can achieve consistent high-quality implants in prostate brachytherapy. *Medical Dosimetry* 37(4):387-90, 3/2012.
 12. Whaley JT, Levy LB, Swanson DA, **Pugh TJ**, Kudchadker RJ, Bruno TL, Frank SJ. Sexual Function and the use of Medical Devices or Drugs to Optimize Potency after Prostate. *Int J Radiat Oncol Biol Phys* 82(5):e765-71, 4/2012. e-Pub 1/2012.

13. **Pugh TJ**, Lee NY, Pacheco T, Raben D. Microcystic adnexal carcinoma of the face treated with radiation therapy: a case report and review of the literature. *Head and Neck* 34(7):1045-50, 7/2012. e-Pub 7/2011.
14. Kim MM, Hoffman KE, Levy LB, Frank SJ, **Pugh TJ**, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease? *Eur J Cancer* 48(11):1664-71, 7/2012. e-Pub 2/2012.
15. Sharp HJ, Swanson DA, **Pugh TJ**, Zhang M, Phan J, Kudchadker R, Bruno TL, Kuban DA, Lee AK, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Frank SJ. Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of rectal complications following brachytherapy. *Practical Radiation Oncology* 2(3):e7-e13, 7/2012. e-Pub 7/2012.
16. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, **Pugh TJ**, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. *Ann Oncol* 23(9):2346-52, 9/2012. e-Pub 2/2012.
17. Albert JM, Swanson DA, **Pugh TJ**, Zhang M, Bruno TL, Kudchadker RJ, Frank SJ. Magnetic resonance imaging-based treatment planning for prostate brachytherapy. *Brachytherapy* 12(1):30-7, 1/2013. e-Pub 6/2012.
18. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, **Pugh TJ**, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. *Int J Radiat Oncol Biol Phys* 85(1):e39-46, 1/2013. e-Pub 10/2012.
19. Brown AP, **Pugh TJ**, Swanson DA, Kudchadker RJ, Bruno TL, Christensen EN, van Vulpen M, Frank SJ. Improving prostate brachytherapy quality assurance with MRI-CT fusion-based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancer. *Brachytherapy*. e-Pub 2/2013.
20. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, **Pugh TJ**, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era? *Int J Radiat Oncol Biol Phys* 85(3):693-9, 3/2013. e-Pub 7/2012.
21. **Pugh TJ**, Choi S, Nguyen QN, Gillen MT, Zhu XR, Palmer M, Lee AK. Proton Therapy for Prostate Cancer. *Practical Radiation Oncology* 3(2):e87-94, 4/2013. e-Pub 7/2012.

22. **Pugh TJ**, Nguyen BN, Kanke JE, Johnson JL, Hoffman KE. Radiation Therapy Modalities in Prostate Cancer. *JNCCN* 1(11(4)):414-21, 4/2013.
23. Register SP, Kudchadker RJ, Levy LB, Swanson DA, **Pugh TJ**, Bruno TL, Frank SJ. An MRI-based dose--reponse analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial. *Brachytherapy* 12(3):210-6, May-Jun, 5/2013. e-Pub 3/2013.
24. **Pugh TJ**, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. *Brachytherapy* 12(3):204-9, May-Jun, 5/2013. e-Pub 6/2012.
25. Takiar V, **Pugh TJ**, Swanson D, Kudchadker RJ, Bruno TL, McAvoy S, Mahmood U, Frank SJ. MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer. *Brachytherapy*. e-Pub 5/2013.
26. Nguyen QN, Levy LB, Lee AK, Choi SS, Frank SJ, **Pugh TJ**, McGuire S, Hoffman K, Kuban DA. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. *Cancer*. e-Pub 6/2013.
27. **Pugh TJ**, Amos RA, John Baptiste S, Choi S, Nhu Nguyen Q, Ronald Zhu X, Palmer MB, Lee AK. Multi-Field Optimization Intensity-Modulated Proton Therapy (MFO-IMPT) for Prostate Cancer: Robustness Analysis through Simulation of Rotational and Translational Alignment Errors. *Med Dosim*. e-Pub 6/2013.
28. Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, **Pugh TJ**, Frank SJ, Kuban DA. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. *Prostate Cancer Prostatic Dis* 16(4):346-51. e-Pub 8/2013.
29. **Pugh TJ**, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA, Frank SJ, Hoffman KE, McGuire SE, Lee AK. Quality of Life and Toxicity From Passively Scattered and Spot-Scanning Proton Beam Therapy for Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys* 87(5):946-53, 12/2013. e-Pub 10/2013.
30. Takiar V, **Pugh TJ**, Swanson D, Kudchadker RJ, Bruno TL, McAvoy S, Mahmood U, Frank SJ. MRI-based sector analysis enhances prostate palladium-103

- brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer. *Brachytherapy* 13(1):68-74, Jan-Feb, 1/2014. e-Pub 5/2013. Mahmood U, **Pugh T**, Frank S, Levy L, Walker G, Haque W, Koshy M, Graber W, Swanson D, Hoffman K, Kuban D, Lee A. Declining use of brachytherapy for the treatment of prostate cancer. *Brachytherapy* 13(2):157-62, Mar-Apr, 3/2014. e-Pub 9/2013.
31. Hoffman KE, Voong KR, **Pugh TJ**, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. *Int J Radiat Oncol Biol Phys* 88(5):1074-84, 4/2014.
 32. Thaker NG, Kudchadker RJ, Swanson DA, Albert JM, Mahmood U, **Pugh TJ**, Boehling NS, Bruno TL, Prestidge BR, Crook JM, Cox BW, Potters L, Moran BJ, Keyes M, Kuban DA, Frank SJ. Establishing High Quality Prostate Brachytherapy Using a Phantom Simulator Program. *Int J Radiat Oncol Biol Phys*. 2014 Aug 20. pii: S0360-3016(14)03408-7.
 33. **Pugh TJ**, Mahmood U, Swanson DA, Munsell MF, Wang R, Kudchadker RJ, Bruno TL, Frank SJ. Sexual Potency Preservation and Quality of Life Following Prostate Brachytherapy and Low-Dose Tadalafil. *Brachytherapy* 2015 Mar-Apr; 14(2):160-5.
 34. **Pugh TJ**, Lee AK. Proton beam therapy for the treatment of prostate cancer. *Cancer J*. 2014 Nov-Dec;20(6):415-20.
 35. Haque W, Wages C, Zhu XR, Choi S, **Pugh TJ**, Frank SJ, Lee A, Mahmood U. Proton therapy for seminoma: Case report describing the technique, efficacy, and advantages of proton-based therapy for seminoma. *Pract Radiat Incol*. 2015 Mar-Apr;5(2):135-40.
 36. Wang J, Kudchadker R, Choi S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, **Pugh TJ**, Hoffman K, Mahmood U, Kuban DA. Local recurrence map guide target volume delineation after radical prostatectomy. *Pract Radiat Oncol* 2014;4(6): e239-46
 37. Zhu XR, Poenisch F, Li H, Zhang X, Sahoo N, Wu RY, Li X, Lee AK, Chang EL, Choi S, **Pugh T**, Frank SJ, Gillin MT, Mahajan A, Grosshans DR. A single-field integrated boost treatment planning technique for spot scanning proton therapy. *Radiat Oncol*. 2014 Sep 11;9:202.
 38. Bian SX, Kuban DA, Levy LB, Oh J, Choi S, McGuire SE, Frank SJ, Mahmood U, Nguyen PL, **Pugh TJ**, Lee AK, Hoffman KE. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-Risk Prostate Cancer. *Am J Clin Oncol*. 2016 Aug; 39(4):368-73.

39. Davis JW, Ward JF 3rd, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, **Pugh TJ**, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. *BJU Int.* 2016 Jul; 118(1):68-76.
40. Grant SR, Walker GV, Koshy M, Shaitelman SF, Frank SJ, **Pugh TJ**, Allen PK, Mahmood U. Impact of Insurance Status on Radiation Treatment Modality Selection Among Potential Candidates for Prostate, Breast, or Gynecologic Brachytherapy. *Int J. Radiat Oncol Biol Phys.* 2015 Dec 1; 93(5):968-75.
41. Thaker NG, **Pugh TJ**, Mahmood U, Choi S, Spinks TE, Martin NE, Sio TT, Kudchadker RJ, Kaplan RS, Kuban DA, Swanson DA, Orto PF, Zelefsky MJ, Cox BW, Potters L, Buchholz TA, Feeley TW, Frank SJ. Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. *Brachytherapy.* 2016 May-Jun; 15(3):274-82.
42. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, **Pugh TJ**. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. *J Clin Oncol.* 2016 Aug 20;34(24):2835-42.
43. Lim TY, Kudchadker RJ, Wang J, Bathala T, Szklaruk J, **Pugh TJ**, Mahmood U, Ibbott GS, Frank SJ. Development of magnetic resonance imaging protocol to visualize encapsulated contrast agent markers in prostate brachytherapy recipients: initial patient experience. *J Contemp Brachytherapy.* 2016 Jun; 8(3):235-42.
44. Hoffman KE, Skinner H, **Pugh TJ**, Voong KR, Levy LB, Choi S, Frank SJ, Lee AK, Mahmood U, McGuire SE, Schlembach PJ, Du W, Johnson J, Kudchadker RJ, Kuban DA. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. *Am J Clin Oncol.* 2016 Sep 15.
45. **Thomas J. Pugh**, Seungtaek Choi, Graciela M. Noguera-Gonzalez, Quynh Nhu Nguyen, Usama Mahmood, Steven J. Frank, Benson Mathai, X. Ron Zhu, Narayan Sahoo, Michael Gillin, Deborah A. Kuban, Karen E. Hoffman, Sean E. McGuire, Andrew K. Lee. Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality of Life Trial. *International Journal of Particle Therapy*, 2016 Volume 3, Issue 1, p27-36.
46. Martin GV, **Pugh TJ**, Mahmood U, Kudchadker RJ, Wang J, Bruno TL, Bathala T, Frank SJ. Permanent prostate brachytherapy pubic arch evaluation with diagnostic MRI. *Brachytherapy.* 2017 Mar 8. pii: S1538-4721(17)30020-X. doi:

10.1016/j.brachy.2017.02.001. PubMed PMID: 28284511.

47. Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, **Pugh TJ**. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. *Urol Oncol*. 2017 Feb 14. pii: S1078-1439(17)30015-7. doi: 10.1016/j.urolonc.2017.01.013. [Epub ahead of print] PubMed PMID: 28214281.
48. **Pugh TJ**, Pokharel SS. Magnetic resonance imaging in prostate brachytherapy: Evidence, clinical end points to data, and direction forward. *Brachytherapy*. 2017 Feb 1. pii: S1538-4721(16)30617-1. doi: 10.1016/j.brachy.2016.12.001. PubMed PMID: 28161432.
49. Jackson MW, Amini A, Jones BL, Kavanagh B, Maroni P, Frank SJ, Mahmood U, Kudchadker RJ, **Pugh TJ**. Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer. *Brachytherapy*. 2017 Jul - Aug;16(4):790-796. doi: 10.1016/j.brachy.2017.03.007. Epub 2017 Apr 23. PubMed PMID: 28442277.
50. Martin GV, **Pugh TJ**, Mahmood U, Kudchadker RJ, Wang J, Bruno TL, Bathala T, Blanchard P, Frank SJ. Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers. *Brachytherapy*. 2017 Jul - Aug;16(4):761-769. doi: 10.1016/j.brachy.2017.04.004. Epub 2017 May 10. PubMed PMID: 28501429.
51. Stokes WA, Kavanagh BD, Raben D, **Pugh TJ**. Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis. *Pract Radiat Oncol*. 2017 Jul - Aug;7(4):270-278. doi: 10.1016/j.ppro.2017.03.011. PubMed PMID: 28673554.
52. K. Ranh Voong, Lincy S. Lai, Deborah A. Kuban, **Thomas J. Pugh**, J. Michael Swint, Joy Godby, Seungtaek Choi, Andrew K. Lee, Pamaela J. Schlembach, Steven J. Frank, Sean E. McGuire, Karen E. Hoffman. The long-term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. *Advance in Radiation Oncology*. Jan 2017; doi: 10.1016/j.adro.2017.07.010
53. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, **Pugh TJ**, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. *BJU Int*. 2018 Apr;121(4):540-548. doi:10.1111/bju.14021. Epub 2017 Oct 17. PubMed PMID: 28941030.

54. Frank SJ, **Pugh TJ**, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW, Kim J, Choi H, Troncoso P, Kuban DA, Choi S, Mcguire S, Hoffman KE, Chen HC, Wang X, Swanson DA. Prospective Phase-2 Trial of Permanent Seed Implantation Prostate Toxicity, and Quality of Life Outcomes. *Int J Radiat Oncol Biol Phys.* 2018 Feb 1; 100 (2): 374-382. Doi 10.1016/i.ijrobp.2017.09.050. Epub 2017 Oct 12. PubMed PMID 29229325
55. Blanchard P, **Pugh TJ**, Swanson DA, Mahmood U, Chen HC, Wang X, Graber WJ,, Kudchadker RJ, Bruno T, Feeley T, Frank SJ. Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study. *Brachytherapy.* 2018 Mar - Apr;17(2):265-276. doi:10.1016/j.brachy.2017.11.007. Epub 2017 Dec 18. PubMed PMID: 29269207.
56. Nath SK, Rose BS, **Pugh TJ**. Who benefits most from early salvage radiation therapy after prostatectomy? *Transl Androl Urol.* 2018 Mar;7(Suppl 1): S124-S127. Doi:10.21037/tau.2017.11.23. Pubmed PMID: 29644179.
57. Robin TP, Maroni PD, Chin BB, La Rosa FG, Bernard B, Pugh TJ. Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy Intensification. *Oncology (Williston Park).* 2018 Jul 15;32(7):360-3, 369, CV3. PubMed PMID: 30080921.
58. Hoffman KR, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, Lee AK, McGuire SE, Nguyen Q, **Pugh TJ**, Frank SJ, Kudchadker RJ, Du W, Kuban DA. Randomized Trial of Hypofractionated, Dose Escalated, Intensity Modulated Radiation Therapy (IMRT) versus Conventionally Fractionated IMRT for localized prostate cancer. *J Clin Oncol.* 2018 Aug 14;JCO2018779868. doi:10.1200/JCO.2018.77.9868. PMID: 30106637

Editorials/Invited Articles

1. **Pugh TJ**, Gaspar LE. Prophylactic cranial irradiation for patients with lung cancer. *Clin Lung Cancer* 8(6):365-8, 5/2007.
2. **Pugh TJ**, Frank SJ. Quality of life issues in the radiotherapeutic management of prostate cancer. *Radiation Medicine Grand Rounds* 2(1), 4/2011.
3. **Pugh TJ**, Raben D. Management of pT3 Prostate Cancer. *AUA Update Series* 30(12):105-112, 2011.

Letters to the Editor

1. Rusthoven KE, **Pugh TJ** Stereotactic Body Radiation Therapy for Inoperable NSCLC: Low incidence of Regional Nodal Failure with SBRT: Radiation Induced Immunotherapy? *Journal of the American Medical Association (JAMA)* 2010 June 16; Vol 303(23)
2. Rusthoven CG, Jones BL, Kavanagh BD, **Pugh TJ**. Reply to J.B. Aragon-Ching and D. Dalela et al. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. *J Clin Oncol* 2016 Dec 12.
3. Rusthoven CG, Jones BL, Kavanagh BD, **Pugh TJ**. Reply to J.B. Aragon-Ching and D. Dalela et al. *J Clin Oncol.* 2017 Mar 10;35(8):916-917. doi: 10.1200/JCO.2016.70.9220. Epub 2016 Dec 12. PubMed PMID: 27937090.

Abstracts

1. **Pugh TJ**, Singh M, Rabinovitch R. First reported case of radiation induced angiosarcoma associated with BRCA2 Mutation following breast conserving therapy. *ASCO Breast Cancer Symposium*, 9/2007.
2. **Pugh TJ**, Ballonoff A, McCammon R, Rusthoven K, Kavanagh B, Rabinovitch R. Decreased Incidence of Cardiac Mortality in Patients with Stages I and II Diffuse Large B-Cell Lymphoma Treated with Radiation: A Surveillance, Epidemiology, and End-Results (SEER) Analysis. *International Journal of Radiation Oncology, Biology, and Physics*, 11/2007.
3. **Pugh TJ**, McCrann K, Kane M, Pervez H, Schefter TE. Combined Modality Treatment for Unresectable Cholangiocarcinoma: A Retrospective Single Institution Experience. *International Journal of Radiation Oncology, Biology, and Physics*, 9/2008.
4. **Pugh TJ**, Ballonoff A, Newman F, Rabinovitch R. Improved Disease Specific and Overall Survival in Patients with Early Stage Low Grade Follicular Lymphoma Treated with External Beam Radiation: A Surveillance, Epidemiology, and End Results Analysis. *International Journal of Radiation Oncology, Biology, and Physics*, 9/2008.
5. Rusthoven KE, Kavanagh B, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, **Pugh TJ**, Franklin W, Kane M, Gasper LE, Schefter TE. Mature Results of a Multi-Institutional Phase I/II of Stereotactic Body Radiation Therapy for Liver Metastases. *Poster Discussion ASCO Gastrointestinal Cancers Symposium*. 1/2009.
6. **Pugh TJ**, Chen C, Rabinovitch R, Eckhardt SG, Rusthoven K, Swing R, Raben D. Phase I Study of bortezomib and concurrent external beam radiation in patients with

advanced solid malignancies. Oral 2/2020ation 91st Annual Meeting of the American Radium Society, 4/2009.

7. **Pugh TJ**, Schefter TE, Kane M, Eckhardt SG, McCarter M, Chen YK, Swing R, Draheim L, Raben D. Phase I Trial of Concurrent Bortezomib, Paclitaxel, and External Beam Radiation in Patients with Unresectable Pancreatic or Billiary Cancer. Poster Viewing for 52nd Annual ASTRO Meeting, 10/2010.
8. M. M. Kim, K. E. Hoffman, L. B. Levy, S. J. Frank, S. Choi, Q. N. Nguyen, **T. Pugh**, S. E. McGuire, A. Lee, D. A. Kuban. Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease? *J Clin Oncol* 29(Suppl 7):Abstract 181, 2/2011.
9. Frank SJ, Munsell MF, **Pugh TJ**, Kudchadker RJ, Bruno TL, Kuban DA, Lee AK, Choi S, Nguyen QN, Swanson DA. Long-Term Outcomes, Quality of Life, and Patient-Reported Satisfaction Following Prostate Brachytherapy: The M.D. Anderson Cancer Center Experience. *Brachytherapy* 10(Supplement 1):S16-17, 5/2011.
10. **Pugh TJ**, Frank SJ, Kudchadker R, Swanson DA, Davis JW. Prostate MRI in Men With Intermediate-Risk Prostate Cancer: Implications for Prostate Brachytherapy Monotherapy. *Brachytherapy* 10(Supplement 1):S30, 5/2011.
11. Kudchadker RJ, **Pugh TJ**, Bruno TL, Du W, Swanson DA, Frank SJ. Optimizing quality assurance in a prospective phase II clinical trial for intermediate risk prostate cancer with brachytherapy as monotherapy using a Palladium-103 stranded seed nomogram. *Med Phys* 38(6):3625, 7/2011.
12. Kudchadker RJ, Du W, Bruno TL, **Pugh TJ**, Frank SJ. Treatment planning dosimetry comparison between model 9011 I-125 thinseed and Model 6711 I-125 seeds for prostate brachytherapy. *Med Phys* 38(6):3625, 7/2011.
13. S. Choi, M. Amin, M. Palmer, X.R. Zhu, Q. Nguyen, **T.J. Pugh**, D.A. Kuban, A.K. Lee. Comparison of Intensity Modulated Proton Therapy (IMPT) to Passively Scattered Proton Therapy (PSPT) in the Treatment of Prostate Cancer. *Int J Radiat Oncol Biol Phys* 81(2):S154-S155, 10/2011.
14. K.O. Castle, K.E. Hoffman, L.B. Levy, A.K. Lee, S. Choi, Q.N. Nguyen, Frank SJ, **T. Pugh**, S.E. McGuire, D.A. Kuban. Is Androgen Deprivation Therapy Necessary in Intermediate Risk Prostate Cancer Patients Treated in the Dose Escalation Era? *Int J Radiat Oncol Biol Phys* 81(2):S40-41, 10/2011.
15. A.P. Brown, **T.J. Pugh**, D.A. Swanson, R.J. Kudchadker, T.L. Bruno, E.N. Christensen, Frank SJ,. mproving Prostate Brachytherapy Quality Assurance with MRI-based Sector Analysis in a Phase II Prospective Trial. *Int J Radiat Oncol Biol Phys* 81(2):S209, 10/2011.

16. **T.J. Pugh**, S.J. Frank, M. Achim, D.A. Kuban, A.K. Lee, S. Choi, Q. Nguyen, K. Hoffman, S.E. McGuire, D.A. Swanson, J.D. Davis. Prediction of Extraprostatic Extension in Intermediate Risk Prostate Cancer: The Evolving Role of Endorectal MRI. *Int J Radiat Oncol Biol Phys* 81(2):S398, 10/2011.
17. E.N. Christensen, **T.J. Pugh**, M.F. Munsell, D.A. Swanson, R.J. Kudchadker, T.L. Bruno, A.P. Brown, Frank SJ. Sector Analysis of Prostate Brachytherapy Shows That Low Doses can Achieve an Undetectable PSA. *Int J Radiat Oncol Biol Phys* 81(2):S422, 10/2011.
18. Q. Nguyen, C. Crawford, M. Palmer, R. Zhu, S. Choi, **T. Pugh**, S.J. Frank, K. Hoffman, D.A. Kuban, A.K. Lee. Utilizing A Multifield Optimization Intensity Modulated Proton Technique (MFO-IMPT) To Deliver A Simultaneous Integrated Boost (SIB) To The Dominant Intraprostatic Lesion For Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys* 81(2):S876-S877, 10/2011.
19. Zhu XR, Grosshans D, Lee A, Choi S, Mahajan A, Chang E, **Pugh T**, Wu R, AMIN M, Palmer M, Taylor M, Gillin M, and Sahoo N. Spot Scanning Proton Therapy: Single Field Simultaneous Integrated Boost. *Med Phys* 38:3602, 2011.
20. Bian S, Kuban DA, Levy LB, Oh J, Castle KO, **Pugh TJ**, Choi S, McGuire SE, Nguyen QN, Frank SJ, Lee AK. Effect of adding short-term androgen deprivation therapy to dose-escalated radiation therapy on failure-free survival for select men with intermediate-risk prostate cancer. *J Clin Oncol* 30(Suppl 5):Abstract 176, 2/2012.
21. **Pugh TJ**, Amos RA, Baptiste SJ, Choi S, Nguyen QN, Zhu XR, Palmer MB, Lee AK. Intensity Modulated Proton Therapy (IMPT) for Prostate Cancer: Robustness Analysis through Simulation of Rotational and Translational Alignment Errors. *Oncology* 26(S1):62-63, 4/2012.
22. Frank SJ, Madden T, Swanson DA, Martirosyan K, Uthamanthil R, Stafford J, Gagea M, **Pugh TJ**, Kudchadker R, Johansen MJ. C4 Markers for MRI-based Prostate Brachytherapy. *Radiotherapy and Oncology* 103(S2):S91, 5/2012.
23. **Pugh TJ**, Swanson DA, Kudchadker RJ, Bruno TL, Munsell MF, Frank SJ. Prospective evaluation of pharmacologic penile rehabilitation following prostate brachytherapy. *Radiotherapy and Oncology* 103(S2):S91-S92, 5/2012.
24. S. Choi, W.E. Umfleet, M.B. Palmer, Q. Nguyen, S.E. McGuire, **T.J. Pugh**, D.A. Kuban, A.K. Lee. Comparison of Scanning Beam Proton Therapy (SBPT) to Intensity Modulated X-ray Therapy (IMRT) for Postoperative Salvage Treatment of Prostate Cancer Patients. *International Journal of Radiation Oncology*Biography*Physics* 84(3):S843-844, 11/2012.
25. U. Mahmood, M. Koshy, **T. Pugh**, K. Hoffman, D. Kuban, A. Lee. Decreasing Utilization of Brachytherapy for the Treatment of Prostate Cancer: A National Pattern

- of Care Analysis Using NCCN Risk Categorization. *International Journal of Radiation Oncology*Biology*Physics*, 84(3):S399, 11/2012.
26. V. Takiar, **T.J. Pugh**, D. Swanson, R. Kudchadker, T.L. Bruno, S. McAvoy, S.J. Frank. MRI-based Sector Analysis Enhances Prostate Pd-103 Brachytherapy Quality Assurance in a Phase II Prospective Trial of Intermediate Risk Patients. *International Journal of Radiation Oncology*Biology*Physics* 84(3):S380-381, 11/2012.
 27. A.K. Lee, S. Choi, Q. Nguyen, **T. Pugh**, B. Mathai, S.J. Frank, K. Hoffman, D. Kuban, S. McGuire, M.F. Munsell. Patient Quality of Life After Proton Therapy (1.8 vs 2 Gray Equivalents) for Prostate Cancer. *International Journal of Radiation Oncology*Biology*Physics* 84(3):S366-367, 11/2012.
 28. **T.J. Pugh**, S. Choi, Q. Nguyen, B. De Gracia, M.F. Munsell, S.J. Frank, D.A. Kuban, K.E. Hoffman, S.E. McGuire, A.K. Lee. Prospective Quality of Life and Toxicity Between Passively Scattered and Spot-Scanning Proton Therapy for Prostate Cancer. *International Journal of Radiation Oncology*Biology*Physics* 84(3):S384, 11/2012.
 29. S.J. Frank, **T. Pugh**, M. Munsell, R. Kudchadker, T. Bruno, D. Kuban, A.K. Lee, S. Choi, S. McGuire, D.A. Swanson. Prostate Brachytherapy Long-term Outcomes, Quality of Life, and Patient-reported Satisfaction. *International Journal of Radiation Oncology*Biology*Physics* 84(3):S392-393, 11/2012.
 30. Q. Nguyen, C. Wages, M. Palmer, S. Choi, **T. Pugh**, D.A. Kuban, A.K. Lee. Scanning Beam Proton Therapy Reduces Dose to Normal Tissue Compared to 3-dimensional X-rays or Passively-Scattered Proton Therapy in Patients With Stage I Seminoma. *International Journal of Radiation Oncology*Biology*Physics*, 84(3):S844-845, 11/2012.
 31. S. Bian, D.A. Kuban, L.B. Levy, J. Oh, S. Choi, S.E. McGuire, **T.J. Pugh**, P.L. Nguyen, A.K. Lee, K.E. Hoffman. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-Risk Prostate Cancer. *International Journal of Radiation Oncology*Biology*Physics* 84(3):S370-371, 11/2012.
 32. H.D. Skinner, K.E. Hoffman, L.B. Levy, A.K. Lee, S.J. Frank, S. Choi, S.E. McGuire, **T.J. Pugh**, D.A. Kuban. Toxicity and Dosimetric Parameters Related to Conventional Versus Dose-Escalated, Hypofractionated Radiation in Prostate Cancer. *International Journal of Radiation Oncology*Biology*Physics* 84(3):S147, 11/2012.
 33. Q. Nguyen, M. Palmer, M. Amin, W.E. Umfleet, S. Choi, **T.J. Pugh**, A.K. Lee. Utilization of Constraints in the Optimization Algorithm With Scanning Beam Proton Therapy Decreases Dose to the Rectum for Patients With Prostate Cancer. *International Journal of Radiation Oncology*Biology*Physics* 84(3):S846-847, 11/2012.

34. Anand A, Du W, Chung H, Frank S, **Pugh T**, Kudchadker R. M.D. Anderson Prostate Seed Implant Dose Calculator. *Medical Physics* 39:3713, 2012.
35. M Yang, W Du, S Frank, **T Pugh**, T Bruno, R Kudchadker. Radiation Exposure Estimation for 131Cs Prostate Implant Patient Release Determination. *Medical Physics* 39:3763, 2012.
36. Rajat J. Kudchadker, Tze Yee Lim, Weiliang Du, Teresa L. Bruno, Usama Mahmood, **Thomas J. Pugh**, Steven J. Frank. 131Cs Stranded-Seed Nomogram for a Prospective Phase II Intermediate-Risk Low-Dose-Rate Prostate Brachytherapy Clinical Trial. *Brachytherapy* 12(S1):S73, 3/2013.
37. Tze Yee Lim, Steven J. Frank, **Thomas J. Pugh**, Teresa L. Bruno, Rajat J. Kudchadker. Comparison of Two Commercial Treatment Planning Systems Variseed and Mim for Low-Dose-Rate Prostate Brachytherapy. *Brachytherapy* 12(S1):S68, 3/2013.
38. Usama Mahmood, Lawrence Levy, Gary Walker, Matthew Koshy, **Thomas Pugh**, Steven Frank, William Graber, Karen Hoffman, Deborah Kuban, Andrew Lee. Declining Use of Brachytherapy for the Treatment of Prostate Cancer. *Brachytherapy* 12(S1):S32, 3/2013.
39. **Thomas J. Pugh**, Rajat Kudchadker, Usama Mahmood, Teresa L. Bruno, Steven J. Frank. Prostate Brachytherapy Treatment Planning Using T2-Weighted Cube 3D Magnetic Resonance Imaging without an Endorectal Coil. *Brachytherapy* 12(S1):S72-73, 3/2013.
40. K. Ranh Voong MD, Deborah A. Kuban MD, James Kanke CMD, Lawrence B. Levy MS, Vinita Takiar MD PhD, **Thomas J. Pugh** MD. Higher baseline urinary symptoms are not associated with increased toxicity from moderately hypofractionated external beam radiation for localized prostate cancer. *Texas Radiological Society*, 4/2013.
41. K. Ranh Voong, MD, **Thomas J. Pugh**, MD, Lawrence B. Levy, Prostate Volume as a Predictor of Toxicity. *American Radium Society Annual Meeting Proceedings*, 4/2013.
42. **Pugh TJ**. The Role of Magnetic Resonance Imaging (MRI) in Prostate Radiation Treatment Planning: Moving Beyond Image Fusion. 37th Annual Meeting of the Gilbert H. Fletcher Society, 4/2013.
43. Jeri Kim, John Francis Ward, Curtis A. Pettaway, Xuemei Wang, Deborah A. Kuban, Steven J. Frank, Andrew Lee, Louis L. Pisters, Surena F. Matin, Jay Bakul Shah, Jose A. Karam, Brian Francis Chapin, John N. Papadopoulos, Mary F. Achim, Karen Elizabeth Hoffman, **Thomas J. Pugh**, Seungtaek Choi, Christopher Logothetis, Patricia Troncoso, John W. Davis. Risk of missing advanced stage or high grade

tumors during active surveillance (AS) even in favorable-risk prostate cancer (PC).
Journal of Clinical Oncology 31:Abstract 5069, 6/2013.

44. Mitcham T, Marques T, Chatterjee D, Krishnan S, **Pugh T**, Bouchard R. Transrectal photoacoustic-ultrasonic imaging for cancer diagnosis and therapy guidance in the prostate. 38th International Symposium on Ultrasonic Imaging and Tissue Characterization, 6/2013.
45. Mitcham T, Marques T, Chatterjee D, Krishnan S, **Pugh T**, Bouchard R. Transrectal photoacoustic-ultrasonic imaging enhancement through interstitial irradiation and targeted. Proceedings of the 2013 IEEE Ultrasonics Symposium, 7/2013.
46. S. Beddar, L. Wootton, R. Kudchadker, S. Choi, **T. Pugh**, A. K. Lee. Online In-Vivo Dosimetry of Rectal Dose Using Plastic Scintillation Detectors for Prostate Patients. 2013 IEEE Nuclear Science Symposium and Medical Imaging Conference, 10/2013.
47. A.K. Lee, S. Choi, Q.N. Nguyen, **T.J. Pugh**, U. Mahmood, B. Mathai, J. Johnson, X. Zhu, T. Ly, M.F. Munsell. Prospective Long-term Patient-Reported Quality of Life After Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology*Biography*Physics 87(2):S74, 10/2013.
48. S. Choi, Q. Nguyen, **T.J. Pugh**, S.J. Frank, K.E. Hoffman, S.E. McGuire, U. Mahmood, D.A. Kuban, A.K. Lee. Proton Therapy for Prostate Cancer Does Not Affect Testosterone Level After Treatment. International Journal of Radiation Oncology*Biography*Physics 87(2):S387-388, 10/2013.
49. S.E. McGuire, J.Z. Cerne, S.R. Grant, M.F. Munsell, A.K. Lee, S.L. Choi, **T.J. Pugh**, S.J. Frank, K.E. Hoffman, D.A. Kuban. The Association of Patient, Tumor, and Treatment Characteristics With Biochemical Response to Neoadjuvant Androgen Deprivation Therapy in Prostate Cancer Patients. International Journal of Radiation Oncology*Biography*Physics 87(2):S384, 10/2013.
50. Vicens RA, Kent S, Jensen CJ, Haque W, Mayo R, Mayo L, **Pugh T**, Klopp A. Brachytherapy gadgets (instruments, applicators, and seeds) that Radiologists should recognize: Pictorial Review. Society of Abdominal Radiology Annual Meeting, 3/2014.
51. Thaker N, Kudchadker, R, Swanson D, Albert J, Mahmood U, **Pugh TJ**, Boehling N, Bruno T, Prestige B, Crook J, Cox B, Potters L, Moran B, Keyes M, Kuban D, Frank S. Establishing High-Quality Prostate Brachytherapy Using a Phantom Simulator Training Program International Journal of Radiation Oncology*Biography*Physics, Volume 90, Issue 3, 1 November 2014, Pages 579-586
52. U. Mahmood, G.V. Walker, L. Levy, **T.J. Pugh**, S.E. McGuire, S. Choi, S.J. Frank, A.K. Lee, D.A. Kuban, K.E. Hoffman, Impact of Insurance Status on Treatment

Selection. International Journal of Radiation Oncology*Biology*Physics, Volume 90, Issue 1, Supplement, 1 September 2014, Page S582

53. **T.J. Pugh**, G. Noguera Gonzalez, S. Choi, U. Mahmood, B. Mathai, M. Munsell, N. Sahoo, M. Gillin, X. Zhu, A.K. Lee, Proton Beam Therapy for Localized Prostate Cancer: A Comparison of Passively Scattered to Intensity Modulated Proton Therapy, International Journal of Radiation Oncology*Biology*Physics, Volume 90, Issue 1, Supplement, 1 September 2014, Pages S54-S55
54. A.K. Lee, G. Noguera Gonzalez, S. Choi, **T.J. Pugh**, U. Mahmood, B. Mathai, M. Munsell, N. Sahoo, M. Gillin, X. Zhu, The Impact of Hormone Therapy on Long-Term Quality of Life in Men Receiving Proton Therapy for Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics, Volume 90, Issue 1, Supplement, 1 September 2014, Page S713
55. Jihong Wang, Tze Yee Lim, Rajat Kudchadker, **Thomas Pugh**, Geoffrey Ibbott, Steven Frank, Evaluation of MR Image Distortion in Positive Contrast Markers for Low-Dose Prostate Brachytherapy, Brachytherapy, Volume 14, Supplement 1, May–June 2015, Page S53
56. Gary V. Walker, Stephen R. Grant, Simona F. Shaitelman, Ann H. Klopp, Steven J. Frank, **Thomas J. Pugh**, Pamela K. Allen, Usama Mahmood, Variation and Impact of Insurance Status Among Non-Elderly Cancer Patients Who Are Potential Candidates for Prostate, Breast, or Gynecologic Brachytherapy, Brachytherapy, Volume 14, Supplement 1, May–June 2015, Page S37
57. Tze Yee Lim, Rajat J. Kudchadker, Jihong Wang, R Jason Stafford, Teresa L. Bruno, Tharakeswara K. Bathala, Usama Mahmood, **Thomas J. Pugh**, Geoffrey Ibbott, Steven J. Frank, Initial Patient Experience With Positive-Contrast MRI Markers for Low-Dose-Rate Prostate Brachytherapy, Brachytherapy, Volume 14, Supplement 1, May–June 2015, Page S35

58. Nikhil G. Thaker, **Thomas J. Pugh**, Usama Mahmood, Tracy E. Spinks, Neil E. Martin, Rajat J. Kudchadker, Alexis B. Guzman, Tiffany M. Jones, LaToi S. Tatum, James R. Incalcaterra, Benjamin D. Frank, John Bingham, Robert S. Kaplan, Caleb Stowell, Thomas A. Buchholz, Deborah A. Kuban, Thomas W. Feeley, Steven J. Frank, Defining the Value Framework for Prostate Brachytherapy Using Patient-Centered Outcome Metrics and Time-Driven Activity-Based Costing, *Brachytherapy*, Volume 14, Supplement 1, May–June 2015, Page S13
59. A.K. Lee, S. Choi, G. Noguera Gonzalez, **T.J. Pugh**, U. Mahmood, M. Munsell, N. Sahoo, X.R. Zhu. Long-Term Outcomes, Toxicity, and Quality of Life after Proton Therapy for Prostate Cancer. *International Journal of Radiation*Oncology*Biology*Physics*, Volume 93, Issue 3, Supplement, 1 November 2015, Pages E207-E208
60. U. Mahmood, J. Huo, M. Koshy, **T.J. Pugh**, S.E. McGuire, S. Choi, S.J. Frank, A. Lee, D.A. Kuban, S. Giordano, T.A. Buchholz, B.D. Smith, K.E. Hoffman. Image Guidance is Associated With Decreased Gastrointestinal Toxicity in Patients Receiving Definitive External Beam Radiation Therapy for Prostate Cancer. *International Journal of Radiation Oncology*Biology*Physics*, Volume 93, Issue 3, Supplement, 1 November 2015, Page E242
61. S. Choi, Q. Nguyen, **T.J. Pugh**, U. Mahmood, S.E. McGuire, K.E. Hoffman, S.J. Frank, D.A. Kuban, A.K. Lee Results of Scanning Beam Proton Therapy (SCBT) for the Treatment of Patients With High-Risk Prostate Cancer. *International Journal of Radiation Oncology*Biology*Physics*, Volume 93, Issue 3, Supplement, 1 November 2015, Pages E243-E244
62. E. Holliday, D.A. Kuban, L.B. Levy, Y. Bolukbasi, P. Master, S. Choi, **T.J. Pugh**, S.E. McGuire, U. Mahmood, S.J. Frank, K.E. Hoffman. Select Men Benefit From Androgen Deprivation Therapy Delivered With Salvage Radiation Therapy After Prostatectomy. *International Journal of Radiation Oncology*Biology*Physics*, Volume 93, Issue 3, Supplement, 1 November 2015, Pages S133-S134
63. Matthew W. Jackson, Arya Amini, Bernard L. Jones, Brian D. Kavanagh, Paul Maroni, Cem Altunbas, **Thomas J. Pugh**, Improved Survival with Brachytherapy as a Component of Definitive Therapy for Favorable High-Risk Prostate Cancer, *Brachytherapy*, Volume 15, Supplement 1, May–June 2016, Pages S22-S23, ISSN 1538-4721,
64. Pierre Blanchard, **Thomas J. Pugh**, David A. Swanson, Usama X. Mahmood, Hsiang-Chun Chang, Xuemei Wang, William J. Graber, Rajat J. Kudchadker, Teresa Bruno, Maria C. Occena, Toweilla G. Henry, Steven J. Frank, Prospective Cohort of Permanent Seed Implantation Prostate Brachytherapy for Intermediate Risk Prostate Cancer: Patient Reported Outcomes and Comparison of Toxicity Profiles between

65. Pierre Blanchard, **Thomas J. Pugh**, Usama X. Mahmood, David A. Swanson, William J. Graber, Jihong Wang, Tharakeswara K. Bathala, Tze Lim, Teresa Bruno, Geoffrey V. Martin, Rajat J. Kudchadker, Steven J. Frank, MRI Simulation for LDR Prostate Brachytherapy: Can We Replace Ultrasound with MRI for Treatment Planning? Comparison of Pre-Planning, Day 0 and Day 30 MR Dosimetry, Brachytherapy, Volume 15, Supplement 1, May–June 2016, Page S57, ISSN 1538-4721.
66. Geoffrey V. Martin, **Thomas J. Pugh**, Usama Mahmood, David A. Swanson, Tze Lim, Rajat Kudchadker, William Graber, Jihong Wang, Teresa Bruno, Tharakeswara K. Bathala, Pierre Blanchard, Steven J. Frank, Are We Ready to Replace Post-Implant CT Dosimetry? Permanent Prostate Brachytherapy Post-Implant MRI Dosimetry Using Positive Contrast MRI Markers, Brachytherapy, Volume 15, Supplement 1, May–June 2016, Pages S189-S190, ISSN 1538-4721.
67. Steven J. Frank, **Thomas J. Pugh**, Pierre Blanchard, Usama X. Mahmood, William J. Graber, Rajat J. Kudchadker, Hsiang-Chun Chang, Xuemei Wang, Teresa Bruno, Toweilla G. Henry, Maria C. Occena, David A. Swanson, Permanent Seed Implantation Prostate Brachytherapy for Intermediate Risk Prostate Cancer: Efficacy and Toxicity Outcomes from a Prospective Cohort of 300 Patients, Brachytherapy, Volume 15, Supplement 1, May–June 2016, Page S201, ISSN 1538-4721.
68. Usama Mahmood, Pierre Blanchard, **Thomas J. Pugh**, David Swanson, William Graber, Rajat Kudchadker, Teresa Bruno, Towella Henry, Maria Occena, Steven Frank, Prospective Cohort of Permanent Seed Implantation Prostate Brachytherapy for Intermediate Risk Prostate Cancer: Analysis of Patient Satisfaction and Interference with Daily Activities between 125-iodine, 103-palladium and 131-cesium, Brachytherapy, Volume 15, Supplement 1, May–June 2016, Pages S201-S202, ISSN 1538-4721.
69. Matthew W. Jackson, Arya Amini, Bernard L. Jones, Brian D. Kavanagh, Paul Maroni, Cem Altunbas, **Thomas J. Pugh**, Improved Survival with Brachytherapy as a Component of Definitive Therapy for Favorable High-Risk Prostate Cancer, Brachytherapy, Volume 15, Supplement 1, May–June 2016, Pages S22-S23
70. U. Mahmood, R. Ye, M. Hernandez, A. Lee, S. Choi, S. Frank, L. Ukegbu, J. Crutison, B. DeGracia, **T. Pugh**. Interim Analysis of a Phase II Trial of Hypofractionated Proton Therapy in Men with Localized Prostate Cancer. International Journal of Particle Therapy, Volume 3, Issue 1, p88
71. Hoffman KE, Voong KR, Levy LB, **Pugh TJ**, Choi S, Du W, Frank SJ, Johnson JL, Kudchadker R, Nguyen QN, Lee A, Mahmood U, McGuire SE, Kuban DA.

Randomized Trial of Hypofractionated Dose-Escalated Intensity Modulated Radiation Therapy Versus Conventionally Fractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys.* 2016 Oct 1;96(2S):S32. doi:10.1016/j.ijrobp.2016.06.091. PubMed PMID: 27675902.

72. Blanchard P, Davis JW, Frank SJ, Jeri K, Pettaway CA, **Pugh TJ**, Pisters LL, Mahmood U, Ward JF, Choi S, Chapin BF, Hoffman KE, Navai N, McGuire SE, Matin SF, Nguyen QN, Thaker NG, Chen HC, Wang X, Kuban DA. How to Counsel Patients With Localized Prostate Cancer About Treatment Selection: Quality-of-Life Results of a Prospective Single-Institution Cohort. *Int J Radiat Oncol Biol Phys.* 2016 Oct 1;96(2S):E534-E535. doi: 10.1016/j.ijrobp.2016.06.1967. PubMed PMID: 27674949.
73. Frank SJ, **Pugh TJ**, Mahmood U, Blanchard P, Kudchadker R, Graber W, Kuban DA, Choi S, Hoffman KE, McGuire SE, Chen HC, Wang X, Thaker NG, Bruno T, Henry TG, Occena MC, Kaplan RS, Feeley TW, Swanson D. The Value of Brachytherapy for Intermediate-Risk Localized Prostate Cancer Using ICHOM Outcomes and Time-Driven Activity-Based Costing: Results From a Phase 2 Prospective Trial of 300 Patients. *Int J Radiat Oncol Biol Phys.* 2016 Oct 1;96(2S):E400-E401. doi:10.1016/j.ijrobp.2016.06.1637. PubMed PMID: 27674592.
74. Martin GV, **Pugh TJ**, Mahmood U, Swanson D, Graber W, Lim TY, Kudchadker R, Wang J, Bruno T, Bathala TK, Blanchard P, Frank SJ. Are We Ready to Replace Postimplant CT Dosimetry? Permanent Prostate Brachytherapy Postimplant MRI Dosimetry Using Positive Contrast MRI Markers. *Int J Radiat Oncol Biol Phys.* 2016 Oct 1;96(2S):E280-E281. doi: 10.1016/j.ijrobp.2016.06.1328. PubMed PMID: 27674258.
75. Amini A, Kavanagh BD, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, **Pugh TJ**. Proton Beam Therapy Utilization and Disparity in the United States for Treatment of Localized Prostate Cancer: A Study of the National Cancer Data Base. *Int J Radiat Oncol Biol Phys.* 2016 Oct 1;96(2S):E244-E245. doi:10.1016/j.ijrobp.2016.06.1238. PubMed PMID: 27674160.
76. Amini A, Maroni P, Kessler ER, Crawford ED, Flaig TW, Bernard B, Raben D, Lam E, **Pugh TJ**. Racial Disparities in Proton Beam Therapy Utilization in the United States. *Int J Radiat Oncol Biol Phys.* 2017 June 1;98(2S):E10. doi:10.1016/j.ijrobp.2017.02.067.
77. Stokes WA, Kavanagh BD, Raben D, Pugh TJ. Implementation of hypofractionated prostate radiotherapy in the United States: A National Cancer Database Analysis. *Int J Radiat Oncol Biol Phys.* 2017 June 1;98(2S): E24-25. doi:10.1016/j.ijrobp.2017.02.131.
78. **TJ Pugh**, BD Kavanagh, SR Plimpton, RJ McCammon, K. Reddy, D Raben. Biochemical Control, Metastases, and Survival Following Moderately

Hypofractionated Intensity Modulated Radiation Therapy Including Elective Treatment of Pelvic Lymphatics: Can We Generalize Results of RTOG 94-01 to Higher Risk Cohorts? *Int J Rad Oncol Biol Phys.* Vol. 99, Issue 2, E260-261. October 2017.

79. WA Stokes, ER Kessler, S Wilson, ET Lam, TW Flaig, BD Kavanagh, **Pugh TJ**. Organ Preservation for Muscle-Invasive Squamous Cell Carcinoma of the Urinary Bladder in the United States. *Int J Rad Oncol Biol Phys.* Vol. 99, Issue 2. E266. October 2017.
80. S. Choi, P Blanchard, R Ye, AK Lee, QN Nguyen, **TJ Pugh**, XR Zhu, N Sahoo, SJ Frank. Outcomes Following Proton Therapy for the Treatment of Prostate Cancer: Efficacy and Toxicity Results from 2 Prospective Single Institution Cohorts. *Int J Rad Oncol Biol Phys.* Vol. 99, Issue 2. E221. October 2017.
81. BF Koontz, KE Hoffman, P Healy, DJ George, MR Harrison, T Zhang, WR Lee, WR Berry, **TJ Pugh**, PG Corn, L Bratt, L Shobe, B Thornburg, DM Allen, K Brummer, B Tojong, B Hobbs, S Halabi, AJ Armstrong. Phase II Trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer. *J Clin Oncol.* Volume 36. Issue 6 Suppl. February 20, 2018
82. B.F. Koontz, K.E. Hoffman, P. Healy, D.J. George, M.R. Harrison, T. Zhang, W.R. Lee, W.R. Berry, **T.J. Pugh**, L. Bratt, B. Hobbs, S. Halabi, P.G. Corn, A. Armstrong, K. Shobe, B. Tojong, B. Thornburg, K. Brummer, D. Allen. Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer. *Int. J. Rad. Onc. Biol. Phys.* Vol 102. Issue 3 S100. Nov 1. 2018

Book Chapters

1. Paul Bunn, York Miller, Nir Peled, Ali Musani, Kavita Garg, Wilbur Franklin, Fred Hirsch, John Mitchell, Michael Weyant, Ross Camidge, Robert Doeble, Laurie Gaspar, Brian Kavanagh, **TJ Pugh**, Jessica Flagiello. Future Directions in the Multidisciplinary Management of Lung Cancer. In: *A Multidisciplinary Approach to Diagnosis and Management*. Ed(s) Kemp Kernstine, Karen Reckamp, Charles Thomas. Demos Medical Publishing, 2010.
2. **Thomas J. Pugh**, Carolyn I. Sartor, Bert O'Neil, David Raben. Gunderson and Tepper Clinical Radiation Oncology 3rd Edition; Chapter 5: Biologics and their interaction with radiation, Third. Ed(s) LL Gunderson, JE Tepper. Elsevier, 83-94, 2011.
3. **Thomas J. Pugh**. Prostate Cancer: A Multidisciplinary Approach to Diagnosis and Management. Chapter 16: Treatment of high-risk prostate cancer: the role of low dose

rate (LDR) and high dose rate (HDR) brachytherapy. Dicker A. Demos Publishing. December 17, 2014

4. Adam Mueller, **Thomas J. Pugh**. Radiation Therapy for Genitourinary Malignancies – A Practical and Technical Guide. Proton therapy for prostate cancer. Solanki and Chen. Springer Nature 2019

Editorial and Review Activities

Ad Hoc Reviewer Cancers 2018-2/2020
Ad Hoc Reviewer, JNCCN, 2018–2/2020
Ad Hoc Reviewer, International Brazilian Journal of Urology, 2018–2/2020
Ad Hoc Reviewer, BMC Cancer, 2017–2/2020
Ad Hoc Reviewer, JAMA Oncology, 2015–2/2020
Ad Hoc Reviewer, Clinical Cancer Research, 2015–2/2020
Ad Hoc Reviewer, American Journal of Clinical Oncology, 2012–2/2020
Ad Hoc Reviewer, Brachytherapy, 2012-2/2020
Ad Hoc Reviewer, Journal of Urology, 2012–2/2020
Ad Hoc Reviewer, Practical Radiation Oncology, 2012–2/2020
Ad-Hoc Reviewer, Radiotherapy and Oncology, 2012–2/2020
Ad Hoc Reviewer, Technology in Cancer Research and Treatment, 2013–2/2020
Ad Hoc Reviewer, Int J Radiat Onc Biol Phys, 2011–2/2020

Regional, National, and International 2/2020ations

Decreased Incidence of Cardiac Mortality in Patients with Stages I and II Diffuse Large B-Cell Lymphoma Treated with Radiation: A Surveillance, Epidemiology, and End-Results (SEER) Analysis, ASTRO, Los Angeles, CA, 10/2007

Improved Disease Specific and Overall Survival in Patients with Early Stage Low Grade Follicular Lymphoma Treated with External Beam Radiation: A Surveillance, Epidemiology, and End Results Analysis, ASTRO, Boston, MA, 9/2008

“Mature Results of a Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases”, ASCO GI Symposium, San Francisco, CA, 1/2009

Phase I study of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies”, American Radium Society, Vancouver, Canada, 4/2009

Prostate MRI in Men with Intermediate-Risk Prostate Cancer: Implications for Prostate Brachytherapy Monotherapy, 32nd Annual Meeting of the American Brachytherapy, San Diego, CA, 4/15/2011

Long-Term Outcomes, Quality of Life, and Patient-Reported Satisfaction Following Prostate Brachytherapy: The MD Anderson Cancer Center Experience, American Urological Association, Washington, D.C., 5/14/2011

Prediction of Extraprostatic Extension in Intermediate Risk Prostate Cancer: The Evolving Role of Endorectal MRI, ASTRO, Miami Beach, FL, 10/3/2011

Integrating into an Academic Practice: From Student to Teacher, The Process of Quality Assurance in Prostate Brachytherapy, Houston, TX, 12/3/2011

Sexual Potency QOL Outcomes and Side Effect Management, The Process of Quality Assurance in Prostate Brachytherapy, Houston, TX, 12/3/2011

Pre-Planned Intra-operative Optimization Technique, The Process of Quality Assurance in Prostate Brachytherapy, Houston, TX, 12/4/2011

Prostate Brachytherapy for Low-Risk Prostate Cancer, Urologic Oncology Advances in Clinical Practice, Houston, TX, 11/3/2012

Multi-Field Optimization Intensity Modulated Proton Therapy for Prostate Cancer: Simulation of Rotational and Translational Alignment Errors, American Radium Society, ARS, Las Vegas, NV, 5/1/2012

Prospective evaluation of pharmacologic penile rehabilitation following prostate brachytherapy, The World Congress of Brachytherapy, ESTRO, Barcelona, 5/10/2012

Prospective Quality of Life and Toxicity between Passively Scattered and Spot-Scanning Proton Therapy for Prostate Cancer”, ASTRO, Boston, MA, 10/29/2012

The Future of Genitourinary Malignancy Research at MD Anderson Cancer Center. Annual Radiation Workshop, Radiation Oncology, Round Top, TX, 11/9/2012

The Role of Magnetic Resonance Imaging (MRI) in Prostate Radiation Treatment Planning: Moving Beyond Image Fusion, Gilbert H. Fletcher Society, Kyoto, Japan, 4/18/2013

Prostate Cancer Imaging, American Brachytherapy Society, New Orleans, LA, 4/20/2013

Contemporary Management of Localized Prostate Cancer, 7th Annual Nursing Knowledge Symposium, Galveston County Gulf Coast Black Nurses Association, Galveston, TX, 6/8/2013

Integration of MRI into Prostate Cancer Radiotherapy, MRI in Radiotherapy, MD Anderson Cancer Center, Houston, TX, 10/28/2013

RTOG 1115: A randomized trial of standard versus enhanced ADT with radiation therapy for high risk prostate cancer, Genitourinary Cancer Research Working Group, Houston, TX, 11/13/2013

MRI Based Post-Implant Dosimetry, The Value and Future of Prostate Brachytherapy in a Changing Healthcare Environment, MD Anderson Cancer Center, 12/7/2013

Quality of Life and Patient Satisfaction in Phase II Clinical Trial of Prostate Brachytherapy for Intermediate Risk Prostate Cancer, The Value and Future of Prostate Brachytherapy in a Changing Healthcare Environment, MD Anderson Cancer Center, Houston, TX, 12/8/2013

The Role of Radiotherapy in Genitourinary Malignancies, University of Texas Medical School Houston, Urology Grand Rounds, Houston, TX, 2/12/2014

The Role of the Radiation Oncologist in Quality and Safety. International Atomic Energy Education Conference, Chicago, IL, 08/25/2014

Time Driven Based Activity Costing and Value Assessments in Oncology. Creighton University Grand Rounds, Omaha, NE, 08/29/2014

Prospective Quality of Life and Toxicity between Passively Scattered and Spot-Scanning Proton Therapy for Prostate Cancer”, ASTRO, San Francisco, CA, 09/15/2014

High Impact Abstract Poster Discussion Session, Moderator, American Brachytherapy Society Annual Meeting, Orlando, FL, 04/11/2015

Hypo-fractionated Radiotherapy for Localized Prostate Cancer: Failed Promises and Future Direction, MD Anderson Cancer Center Graduate Medical Educational Series, Houston, TX, 09/02/2015

Time to Cover Proton Therapy for Prostate Cancer, MD Anderson Cancer Center 2nd National Education Conference, Houston, TX, 09/11/2015

MR Correlation with Prostate Pathology, The Utilization of MRI in LDR and HDR Prostate Brachytherapy: From Diagnosis to Response Assessment. Houston, TX. 11/7/2015

MD Anderson Phase II Trial of Monotherapy for Intermediate Risk Localized Prostate Cancer, The Utilization of MRI in LDR and HDR Prostate Brachytherapy: From Diagnosis to Response Assessment. Houston, TX. 11/8/2015

What’s new in Radiation Therapy for Bladder Cancer? Rocky Mountain Urologic Society Annual Meeting, Centennial, CO. 04/08/2016

Prostate Cancer Snap Oral 2/2020ations, Session Moderator, World Congress of Brachytherapy, San Francisco, CA 06/28/2016

An Open Discussion on Advanced Radiation Therapy for Prostate Cancer Including Proton Therapy, SBRT (Cyberknife), Brachytherapy, and IMRT. University of Colorado Prostate Cancer Education and Support Group, Aurora, CO 9/13/2016

Update on Radiation Therapy for Localized Prostate Cancer: Dose, Fractionation Schedules, and Emerging Adjuncts to Therapy. Annual UCHHealth Oncology GU Retreat. Fort Collins, CO 11/4/2016

Biochemical control, metastases, and survival following moderately hypo-fractionated pelvic intensity modulated radiation therapy with synchronous integrated boost to the pelvic lymphatics: Can we generalize the results of RTOG 0415 to higher risk cohorts? Practical Management Strategies and New Innovation in Prostate Radiotherapy. Memorial Sloan Kettering Cancer Center. New York, NY 12/8/2016.

Efficacy of prostate brachytherapy from low to high risk: summary of the Phase II/III data. American Brachytherapy Society Annual Meeting 2017. Boston, MA 04/20/2017.

Management of Localized Prostate Cancer: What the medical oncologist needs to know. University of Colorado Hospital Medical Oncology Fellows Educational Conference. Denver, Colorado 04/28/2017.

Advances in Radiation Therapy for Localized Prostate Cancer
11th Annual Mountain States Cancer Conference
Aurora, CO
October 14th, 1017

The Demise of Prostate Brachytherapy in the United States
University of Wisconsin Visiting Professor Lectures Series
Madison, Wisconsin
October 20th, 2017

Challenging cases in Urologic Oncology – Panel Member
Regional Meeting of the American Urologic Association
Naples, Florida
November 28, 2017

Management of Oligometastatic Prostate Cancer
28th International Prostate Cancer Update
Beaver Creek, Colorado
January 25, 2018

Diagnosis and Multi-modality Treatment of Localized Prostate Cancer – Session Chair

2018 ASCO Genitourinary Cancer Symposium
San Francisco, CA
February 8th, 2018

Management of Oligometastatic Prostate Cancer
Mexican Urology Consortium
Aurora, Colorado
June 12th, 2018

Contemporary Post-Prostatectomy Management of High-Risk Prostate Cancer
Urology Grand Rounds
Aurora, CO
July 16th, 2018

Advances in the Treatment of Muscle-Invasive Bladder Cancer
2018 NCCN Oncology Tumor Board
July 25, 2018

Future Directions in Prostate Brachytherapy
19th Annual Future Directions in Urology Symposium
Colorado Springs, CO
August 13th, 2018

Updates on radiation therapy clinical pathways for intact prostate cancer and the current
role of SABR/SBRT
Annual UCHHealth System-Wide GU Oncology Retreat
Aurora, CO
November 2, 2018

MD Anderson Phase II Trial of Monotherapy for Intermediate-Risk Localized Prostate
Cancer
ABS-MD Anderson Prostate and GYN School
Houston, TX
November 30th, 2018

Clinical Research Protocols

2013-0982: Phase II trial of abiraterone acetate, radiotherapy and short-term androgen deprivation in men with unfavorable risk localized prostate cancer. 2013-2015. Active Accrual. **Co-Principle Investigator/Retired**

2013-0555: PARTIQoL: Prostate Advanced Radiation Technologies Investigating Quality of Life. A Phase III trial comparing intensity modulated radiation therapy to proton therapy for localized prostate cancer. 2012-2015. Funded by the National Cancer Institute. **Co-Principle Investigator/Retired**

2013-0855: MRI simulation for treatment of localized prostate cancer. 2013-2015. Funded by Elekta Corporation; **Principle Investigator/Retired**

2012-1003: Phase II Trial of hypofractionated proton beam therapy in men with localized prostate adenocarcinoma, 2012–2015. Funded by the John and Cher Floyd Prostate Cancer Research Fund. **Principal Investigator/Retired**

2012-1013: A Pilot Study for the Identification of MRI Markers in Prostate Brachytherapy, 2013–2014. Funded by C4-Imaging. **Principal Investigator** – Closed following 410k approval

RTOG0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer, RTOG 0815, National PI - Alvaro A. Martinez, 2012–2013, Funded by the Radiation Therapy Oncology Group. **Institutional Principle Investigator/Closed to Accrual**

RTOG1115-Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer, RTOG1115, National PI - M. Dror Michaelson, 2013–2014 (CLOSED). Funded by the Radiation Therapy Oncology Group. **Institutional Principle Investigator/Closed by Sponsor**

COMIRB 15-0682/NRG GU001: A Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer. **Institutional Principle Investigator/Retired**

COMIRB 15-1671/ATLAS: A Randomized Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy. **Institutional Principle Investigator/Closed-Full Accrual**

COMIRB 18-0285/NRG GU005: PHASE III IGRT AND SBRT VS IGRT AND HYPOFRACTIONATED IMRT FOR LOCALIZED INTERMEDIATE RISK PROSTATE CANCER. **Institutional Principle Investigator/Active**

COMIRB 17-2037/NRG GU003: A RANDOMIZED PHASE III TRIAL OF HYPOFRACTIONATED POST-PROSTATECTOMY RADIATION THERAPY (HYPORT) VERSUS CONVENTIONAL POST-PROSTATECTOMY RADIATION THERAPY (COPORT). **Institutional Principle Investigator/Closed-Full Accrual**

Grant Funding

Elekta Technology Development Grant, “MRI based simulation and treatment planning for localized prostate cancer. (\$26,490/year with annual renewal for up to five years). Awarded 5/2013.

NIH/NCI Odyssey Fellowship Grant Development and Optimization of a Photoacoustic-Ultrasonic Transrectal Imaging System for the Improved Visualization of Prostate Brachytherapy Seeds, P50 CA140388, NIH/NCI, PI - Richard Brouhard, \$50,000 (\$50,000/year)

John and Cher Floyd Prostate Cancer Research Fund. Fund Steward - Retired

RTOG 1115 “RTOG 1115-Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer. (Total \$225,000), RTOG

Dana Farber Cancer Institute/Massachusetts General Hospital/National Cancer Institute PARTIQoL: Prostate Advanced Radiation Technologies Investigating Quality of Life. A Phase III trial comparing intensity modulated radiation therapy to proton therapy for localized prostate cancer. (Total \$140,000).

Educational Activities

Formal Teaching

American Brachytherapy Society LDR Prostate Brachytherapy Scholarship Program: **Co-Director and Curriculum Coordinator** hosting intensive educational program for senior resident and junior attending physicians seeking supplemental training in prostate brachytherapy. 7/2010-10/2015

Recurring Genitourinary Oncology Didactic Lecture Curriculum – 11/2015-2/2020

Introduction to LDR Prostate Brachytherapy
Post-operative Radiation Therapy for Prostate Cancer
Organ Preservation for Muscle Invasive Bladder Cancer
Secondary Cancer Risk following pelvic radiation therapy
Management of Stage I-II testicular seminoma
Dose-Escalation and Altered Fractionation for Localized Prostate Cancer

Educational Conference/Symposia Organization

2018 ABS-MD Anderson Prostate School and LDR/HDR Workshop

Clinical Management – New Brachytherapy Data – Session Chair/Moderator
Houston, TX
November 30th, 2018

2018 ASCO Genitourinary Cancer Symposium
Diagnosis and Multi-modality Treatment of Localized Prostate Cancer – Session Chair
San Francisco, CA
February 8th, 2018

2018 ASCO Genitourinary Cancer Symposium
Oral Abstract Session A: Prostate Cancer – Session Chair
San Francisco, CA
February 8th, 2018

American Brachytherapy Society Annual Meeting 2018
Scientific Program Committee - Genitourinary Chair
San Francisco, CA 6/2018

ASCO Genitourinary Cancers Symposium 2018
Program Committee Member
San Francisco, CA 2/2018

North American Proton Therapy Oncology Group Annual Meeting,
Co-Chairman and Director of Genitourinary Tract
Houston, TX 10/2014

The Value and Future of Prostate Brachytherapy in a Changing Healthcare System,
Co-Chairman and Program Developer
Houston, TX 12/2013

The Utilization of MRI in LDR and HDR Prostate Brachytherapy: From Diagnosis to Response Assessment
Co-Chairman and Program Developer
Houston, TX. 11/8/2015

March MAN-ness Metro Denver Community Educational Conference
Oncology Question and Answer
Centennial, CO 3/10/2016

Supervisory Post-Graduate Teaching

Mirna Abboud MD	7/2010–8/2010
Jillian Tsai MD PhD	8/2010–9/2010
Eva Christensen MD PhD	9/2010–10/2010
Kate Castle MD	10/2010–11/2010
Christine Fisher MD	11/2010–12/2010
Jeff Albert MD PhD	12/2010–1/2011
Henry Mok MD PhD	1/2011–2/2011
Hadi Zahra MD	2/2011–3/2011
Aaron Brown MD	2/2011–3/2011
David Weksberg MD PhD	3/2011–4/2011
Ben Moeller MD PhD	4/2011–5/2011
Eugene Koay MD	5/2011–6/2011
Grace Smith MD PhD	6/2011–7/2011
Michelle Kim MD PhD	7/2011–8/2011
Rang Voong MD	8/2011–9/2011
Jingya Wang MD	9/2011–10/2011
Hiral Fontanilla MD	11/2011–12/2011
Sarah McAvoy MD	12/2011–1/2012
Hadley Sharp MD	1/2012–2/2012
Eugene Lee MD	2/2012–3/2012
Matthew Wszolek MD	2/2012–3/2012
Neema Navai MD	2/2012–3/2012
Patrick Kenney MD	2/2012–3/2012
Saad Aldousari MD	2/2012–3/2012
Vinita Takiar MD PhD	2/2012–3/2012
Joella Wilson MD	3/2012–4/2012
Jonathan Grant MD	4/2012–5/2012
Sonali Rudra MD	4/2012–5/2012
Gary Walker MD	5/2012–6/2012
Usama Mahmood MD	5/2012–6/2012
Dharma Macdermed MD	6/2012–7/2012
Nguyen Dang MD	6/2012–7/2012
Emma Holliday MD	10/2012–11/2012
Mark Edson MD PhD	11/2012–12/2012
Lauren Layer MD	12/2012–1/2013
Andrew Bishop MD	1/2013–2/2013
Nicholas Boehling MD	3/2013–4/2013
Shervin Shirvani MD	4/2013–5/2013
Jeffrey Albert MD	6/2013–7/2013
Nikhil Thaker MD	6/2013–7/2013
Jared Sturgeon MD PhD	1/2014–3/2014
Jay Reddy MD	1/2014–3/2014
Brad Greenfield MD	2/2014–3/2014
Chad Tang MD	3/2014–4/2014

Eleanor Osborne MD	4/2014-5/2014
Jillian Gunther MD, PhD	5/2014-6/2014
Cameron Swanick MD	6/2014-7/2014
Jennifer Ho MD	7/2014-8/2014
Hubert Pan MD	8/2014-10-2014
AJ Echeveria MD	10/2014-11/2014
Geoff Martin MD	11/2014-12/2014
Aaron Grossberg MD	12/2014-1/2015
Brian Deegan MD	3/2015-5/2014
Chisaroka Echendu MD	4/2015-5/2015
Wen Jiang MD	5/2015-6/2015
Jennifer Logan MD	7/2015-8/2015
Lauren Colbert MD	8/2015-9/2015
Tommy Sheu MD	9/2015-10/2015
Courtney Pollard MD, PhD	10/2015-11/2015
Priscilla Stumpf MD	11/2015-12/2015
Tyler Robin MD, PhD	1/2016-3/2016
Gentry King MD	2/2016-3/2016
Tim Waxweiler MD	4/2016-6/2016
Brian Miller MS	7/2016-8/2016
David Binder MD PhD	7/2016-9/2016
Arya Amini MD	8/2016-9/2016
Jennifer McDonald PharmD	9/2016 -10/2016
Adam Mueller MD PhD	10/2016-12/2016
Supriya Jain MD	1/2017-3/2017
Tyler Robin MD PhD	4/2017-6/2017
Doug Holt MD	7/2017-9/2017
Priscilla Stumpf MD	10/2017-12/2017
William Stokes MD	1/2018-3/2018
David Binder MD PhD	4/2018-6/2018
Adam Mueller MD PhD	7/2018-9/2018
Supriya Jain MD	10/2018-12/2018
Sara Zakem MD	01/2019-03/2019

Medical Student Advisory/Supervisory Teaching

Colton Ladbury MS1	1/2016-2/2016
Doug Rooke MS4	6/2016-7/2016
Whitney Sumner MS4	7/2016-8/2016
Leon Reshko MS4	7/2016-8/2016
Cameron Callaghan MS4	8/2016-9/2016
Jared Rowley MS4	8/2016-9/2016
Reed Plimpton MS4	9/2016-10/2016
Michael Dohopolski	6/2017-7/2017
Kevin Quackenbush MS4	6/2017-7/2017
Arpan Prabhu MS4	7/2017-8/2017
Noah Kastelwicz-Lieberman MS4	7/2017-8/2017

Jordan Gainey MS4	8/2017-9/2017
Daniel Detische MS4	8/2017-9/2017
Craig Schneider MS4	9/2017-10/2017
Samantha King MS4	9/2017-10/2017
Anna Astashchanka MS4	1/2018-2/2018
Colton Ladbury MS3	5/2018-6/2018
Abhinav Gupta MS4	5/2018-6/2018
Alison Kremer MS4	7/2018-8/2018
Kaitlin Qualls MS4	7/2018-8/2018
Jacob Hall MS4	8/2018-9/2018
Jacob Langston MS4	8/2018-9/2018
Taylor Cushman MS4	09/2018-10/2018
Ahsen Ahmed MS4	09/2018-10/2018

Formal Mentees

Tyler Robin MD, PhD Resident Physician University of Colorado Denver Department of Radiation Oncology	7/2017-2/2020
--	---------------

Usama Mahmood MD Assistant Professor University of Texas MD Anderson Cancer Center Division of Radiation Oncology	7/2012-10/2015
--	----------------

Matt Jackson MD PGY-4 Improved Survival with Brachytherapy as a Component of Definitive Therapy for Favorable High Risk Prostate Cancer Plenary Session – Top Abstract Award World Congress of Brachytherapy 2016 Published Manuscript Brachytherapy	5/2016-9/2016
--	---------------

Arya Amini MD PGY-5 Racial Disparities in Proton Beam Therapy Utilization in the United States Oral 2/2020ation Top Scientific Submission Travel Grant Award American Radium Society Annual Meeting - 2017	5/2016-5/2017
---	---------------

Technical Skills

Intensity modulated radiation therapy (**IMRT**) for head and neck, central nervous system, thoracic, gastrointestinal, and genitourinary malignancies.

Stereotactic body radiation therapy (**SBRT**) for lung cancer, prostate cancer, liver metastases, and lung metastases

Stereotactic radiosurgery (**SRS**) using gamma-knife or linear accelerator platforms for treatment of intracranial and/or spinal diseases

Nationally accredited expert on permanent interstitial **prostate brachytherapy** maintaining a high volume brachytherapy practice at a tertiary cancer center

Proficient with multiple **radiation treatment planning** systems including Pinnacle, Eclipse, XiO, Variseed, BrainLab, and MiMVista

Technical expertise using a variety of **linear accelerator platforms** including Elekta Synergy, Varian Trilogy, Novalis BrainLab, and Tomotherapy

Internationally recognized authority on passively scattered **proton therapy** and intensity modulated proton therapy (**IMPT**) for prostate cancer

References

Available on Request